Artivion, Inc. (NYSE:AORT) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its holdings in shares of Artivion, Inc. (NYSE:AORT) by 7.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 13,393 shares of the company’s stock after buying an additional 968 shares during the period. SG Americas Securities LLC’s holdings in Artivion were worth $239,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Money Concepts Capital Corp acquired a new stake in shares of Artivion during the 4th quarter worth about $28,000. Tower Research Capital LLC TRC grew its stake in Artivion by 89.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,677 shares of the company’s stock worth $29,000 after buying an additional 791 shares during the last quarter. Captrust Financial Advisors purchased a new position in Artivion during the 2nd quarter worth approximately $39,000. State of Wyoming grew its stake in Artivion by 207.1% during the 4th quarter. State of Wyoming now owns 3,495 shares of the company’s stock worth $42,000 after buying an additional 2,357 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its stake in Artivion by 54.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,859 shares of the company’s stock worth $47,000 after buying an additional 1,353 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Trading Down 0.7 %

Shares of AORT stock opened at $21.32 on Friday. The business’s 50 day moving average is $19.60 and its two-hundred day moving average is $17.33. Artivion, Inc. has a twelve month low of $12.16 and a twelve month high of $21.90. The company has a market capitalization of $878.38 million, a P/E ratio of -28.43 and a beta of 1.67. The company has a current ratio of 4.85, a quick ratio of 3.43 and a debt-to-equity ratio of 1.10.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, February 15th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.24. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. The company had revenue of $93.67 million for the quarter, compared to the consensus estimate of $89.75 million. Equities analysts forecast that Artivion, Inc. will post 0.26 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, CEO James P. Mackin sold 13,996 shares of Artivion stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $18.72, for a total value of $262,005.12. Following the transaction, the chief executive officer now directly owns 705,562 shares in the company, valued at approximately $13,208,120.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Andrew M. Green sold 1,462 shares of Artivion stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $20.00, for a total value of $29,240.00. Following the sale, the vice president now directly owns 41,121 shares in the company, valued at $822,420. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO James P. Mackin sold 13,996 shares of Artivion stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $18.72, for a total value of $262,005.12. Following the completion of the sale, the chief executive officer now owns 705,562 shares in the company, valued at $13,208,120.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 149,952 shares of company stock worth $2,891,627. 6.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $25.00 price target on shares of Artivion in a research note on Monday. Stifel Nicolaus raised their price target on Artivion from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 16th.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.